Triple negative breast cancers (TNBCs), characterized by lack of estrogen, progesterone and HER2 receptors, are a highly heterogenous group of tumors which account for about 20% to 25% of all breast cancers. TNBCs are often associated with epithelial-mesenchymal transition and a high propensity for early metastasis. Since no molecularly-targeted therapeutic agents are clinically available for TNBCs, these tumors, which are frequently resistant to cytotoxic chemotherapy, remain difficult to treat. Nevertheless, progress is being made in the finding of molecular alterations typical of TNBCs toward which to focus therapeutic efforts.
Labbozzetta, M., Poma, P., Vivona, N., D’Alessandro, N., NOTARBARTOLO DI VILLAROSA, M. (2015). NF-κB is a potential pharmacological target in triple negative breast cancers.. In Atti del 37° Congresso Nazionale della Società Italiana di Farmacologia.
NF-κB is a potential pharmacological target in triple negative breast cancers.
LABBOZZETTA, Manuela;POMA, Paola;VIVONA, Nicoletta;D'ALESSANDRO, Natale;NOTARBARTOLO DI VILLAROSA, Monica
2015-01-01
Abstract
Triple negative breast cancers (TNBCs), characterized by lack of estrogen, progesterone and HER2 receptors, are a highly heterogenous group of tumors which account for about 20% to 25% of all breast cancers. TNBCs are often associated with epithelial-mesenchymal transition and a high propensity for early metastasis. Since no molecularly-targeted therapeutic agents are clinically available for TNBCs, these tumors, which are frequently resistant to cytotoxic chemotherapy, remain difficult to treat. Nevertheless, progress is being made in the finding of molecular alterations typical of TNBCs toward which to focus therapeutic efforts.
| File | Dimensione | Formato | |
|---|---|---|---|
|
congresso sif 2015.pdf
accesso aperto
Dimensione
1.9 MB
Formato
Adobe PDF
|
1.9 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
